Yale Cancer Center shared on LinkedIn:
“In a new study led by Dr. Roel Verhaak, Harvey and Kate Cushing Professor of Neurosurgery, results revealed that two types of gliomas – astrocytomas and oligodendrogliomas – develop radically different mutations as they become more treatment resistant. Gliomas represent 33% of brain cancers.
The findings suggest that future glioma treatments may need to be type-specific, rather than generic, says Dr. Verhaak.”
Other articles featuring Yale Cancer Center on OncoDaily.